B
Bastiaan E. de Galan
Researcher at Maastricht University
Publications - 107
Citations - 8886
Bastiaan E. de Galan is an academic researcher from Maastricht University. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 20, co-authored 67 publications receiving 7942 citations. Previous affiliations of Bastiaan E. de Galan include Radboud University Nijmegen Medical Centre & Royal Prince Alfred Hospital.
Papers
More filters
Journal ArticleDOI
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel,Stephen MacMahon,John Chalmers,Bruce Neal,Laurent Billot,Mark Woodward,Mark Woodward,Michel Marre,Mark E. Cooper,Paul Glasziou,Paul Glasziou,Diederick E. Grobbee,Pavel Hamet,Stephen B. Harrap,Simon Heller,Lisheng Liu,Giuseppe Mancia,Carl Erik Mogensen,C. Y. Pan,Neil R Poulter,Anthony Rodgers,Bryan Williams,Severine Bompoint,Bastiaan E. de Galan,Bastiaan E. de Galan,Rohina Joshi,F. Travert +26 more
TL;DR: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21%relative reduction in nephropathy.
Journal ArticleDOI
Caffeine Can Decrease Insulin Sensitivity in Humans
TL;DR: Caffeine can decrease insulin sensitivity in healthy humans, possibly as a result of elevated plasma epinephrine levels, and peripheral adenosine receptor antagonism does not appear to contribute to this effect.
Journal ArticleDOI
Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes
Stephanie A. Amiel,Pablo Aschner,Belinda Childs R N,Philip E. Cryer,Bastiaan E. de Galan,Simon Heller,Brian M. Frier,Linda Gonder-Frederick,Timothy W. Jones,Kamlesh Khunti,Lawrence A. Leiter,Rory J. McCrimmon,Yingying Luo,Elizabeth R. Seaquist,Robert A. Vigersky,Sophia Zoungas +15 more
TL;DR: The International Hypoglycaemia Study Group recommends that the frequency of detection of a glucose concentration <3.0 mmol/l (<54 mg/dl), which it considers to be clinically significant biochemical hypoglycaemic, be included in reports of clinical trials of glucoselowering drugs evaluated for the treatment of diabetes mellitus.
Journal ArticleDOI
Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management
Stephanie A. Amiel,Pablo Aschner,Belinda P. Childs,Philip E. Cryer,Bastiaan E. de Galan,Brian M. Frier,Linda Gonder-Frederick,Simon Heller,Timothy W. Jones,Kamlesh Khunti,Lawrence A. Leiter,Yingying Luo,Rory J. McCrimmon,Ulrik Pedersen-Bjergaard,Elizabeth R. Seaquist,Sophia Zoungas +15 more
TL;DR: New evidence suggests that the association between hypoglycaemia and cardiovascular events and mortality is likely to be multifactorial, and this risk should be recognised by clinicians when agreeing glycaemic goals with patients and choosing appropriate glucose-lowering therapies.
Journal ArticleDOI
Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
Xin Du,Toshiharu Ninomiya,Bastiaan E. de Galan,Bastiaan E. de Galan,Edward Abadir,John Chalmers,Avinesh Pillai,Mark Woodward,Mark Woodward,Mark E. Cooper,Stephen B. Harrap,Pavel Hamet,Neil R Poulter,Gregory Y.H. Lip,Anushka Patel +14 more
TL;DR: Atrial fibrillation is relatively common in type 1 diabetes and is associated with substantially increased risks of death and cardiovascular events in patients with type 2 diabetes, and this arrhythmia identifies individuals who are likely to obtain greater absolute benefits from blood pressure-lowering treatment.